Single nucleotide polymorphisms in toll-like receptor 6 are associated with altered lipopeptide- and mycobacteria-induced interleukin-6 secretion

Genes and Immunity

Volumn 11, Issue 7, 2010, Pages 561-572

  Shey, M S ^a   Randhawa, A K ^b   Bowmaker, M ^a   Smith, E ^a   Scriba, T J ^a   De Kock, M ^a   Mahomed, H ^a   Hussey, G ^a   Hawn, T R ^b   Hanekom, W A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

immune response; interleukin 6; polymorphism; toll like receptor 6; tuberculosis

Indexed keywords

BCG VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPEPTIDE; LIPOPEPTIDE PAM2; TOLL LIKE RECEPTOR 6; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CYTOKINE RELEASE; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; INFECTION SENSITIVITY; INNATE IMMUNITY; MALE; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CYTOKINES; HEK293 CELLS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-6; LIPOPEPTIDES; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 6; TOLL-LIKE RECEPTORS;

CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

EID: 77958153817     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2010.14     Document Type: Article

References (47)

1. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 2006; 27: 49-55.
2. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
3. Beutler B. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 2009; 227: 248-263.
4. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009; 227: 221-233.
5. Hill AV. Aspects of genetic susceptibility to human infectious diseases. Annu Rev Genet 2006; 40: 469-486.
6. Misch EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci (Lond) 2008; 114: 347-360.
7. Hill AV. The genomics and genetics of human infectious disease susceptibility. Annu Rev Genomics Hum Genet 2001; 2: 373-400.
8. Hawn TR, Misch EA, Dunstan SJ, Thwaites GE, Lan NT, Quy HT et al. A common human TLR1 polymorphism regulates the innate immune response to lipopeptides. Eur J Immunol 2007; 37: 2280-2289.
9. Johnson CM, Lyle EA, Omueti KO, Stepensky VA, Yegin O, Alpsoy E et al. Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 2007; 178: 7520-7524.
10. Wurfel MM, Gordon AC, Holden TD, Radella F, Strout J, Kajikawa O et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 2008; 178: 710-720.
11. Omueti KO, Beyer JM, Johnson CM, Lyle EA, Tapping RI. Domain exchange between human toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination. J Biol Chem 2005; 280: 36616-36625.
12. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A et al. Discrimination of bacterial lipoproteins by toll-like receptor 6. Int Immunol 2001; 13: 933-940.
13. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169: 10-14.
14. Buwitt-Beckmann U, Heine H, Wiesmuller KH, Jung G, Brock R, Akira S et al. TLR1-and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem 2006; 281: 9049-9057.
15. Morr M, Takeuchi O, Akira S, Simon MM, Muhlradt PF. Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur J Immunol 2002; 32: 3337-3347.
16. Brightbill HD, Modlin RL. Toll-like receptors: molecular mechanisms of the mammalian immune response. Immunology 2000; 101: 1-10.
17. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999; 163: 3920-3927.
18. Underhill DM, Ozinsky A, Smith KD, Aderem A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci USA 1999; 96: 14459-14463.
19. Bulut Y, Faure E, Thomas L, Equils O, Arditi M. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol 2001; 167: 987-994.
20. Dhiman N, Ovsyannikova IG, Vierkant RA, Ryan JE, Shane Pankratz V, Jacobson RM et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 2008; 26: 1731-1736.
21. Hoffjan S, Stemmler S, Parwez Q, Petrasch-Parwez E, Arinir U, Rohde G et al. Evaluation of the toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Med Genet 2005; 6: 34.
22. Tantisira K, Klimecki WT, Lazarus R, Palmer LJ, Raby BA, Kwiatkowski DJ et al. Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes Immun 2004; 5: 343-346.
23. Kesh S, Mensah NY, Peterlongo P, Jaffe D, Hsu K, M VDB et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci 2005; 1062: 95-103.
24. WHO. Global Tuberculosis Control: Epidemiology, Strategy, Financing. WHO Report 2009. World Health Organisation, Geneva, Switzerland, 2009, (WHO/HTM/TB/2009.411).
25. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 2005; 202: 1715-1724.
26. Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, Musser JM. Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One 2007; 2: e1318.
27. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000; 68: 6398-6401.
28. Schroder NW, Diterich I, Zinke A, Eckert J, Draing C, von Baehr V et al. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burg-dorferi and protects from late stage Lyme disease. J Immunol 2005; 175: 2534-2540.
29. Schroder NW, Hermann C, Hamann L, Gobel UB, Hartung T, Schumann RR. High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR. J Mol Med 2003; 81: 368-372.
30. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005; 5: 156-164.
31. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
32. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X et al. Defective LPS signaling in C3H/HeJ and C57BL/ 10ScCr mice: mutations in Tlr4 gene. Science (NY) 1998; 282: 2085-2088.
33. Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1: 304-313.
34. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003; 4: 117.
35. Barreiro LB, Ben-Ali M, Quach H, Laval G, Patin E, Pickrell JK et al. Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense. PLoS Genet 2009; 5: e1000562.
36. Okusawa T, Fujita M, Nakamura J, Into T, Yasuda M, Yoshimura A et al. Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6. Infect Immun 2004; 72: 1657-1665.
37. Muller SD, Muller MR, Huber M, Esche Uv U, Kirschning CJ, Wagner H et al. Triacyl-lipopentapeptide adjuvants: TLR2-dependent activation of macrophages and modulation of receptor-mediated cell activation by altering acyl-moieties. Int Immunopharmacol 2004; 4: 1287-1300.
38. Rwan M, Grau T, Tschumi A, Sander P. Lipoprotein synthesis in mycobacteria. Microbiology 2007; 153: 652-658.
39. Pecora ND, Gehring AJ, Canaday DH, Boom WH, Harding CV. Mycobacterium tuberculosis LprA is A lipoprotein agonist of TLR2 that regulates innate immunity and APC function. J Immunol 2006; 177: 422-429.
40. Henneke P, Dramsi S, Mancuso G, Chraibi K, Pellegrini E, Theilacker C et al. Lipoproteins are critical TLR2 activating toxins in group B streptococcal sepsis. J Immunol 2008; 180: 6149-6158.
41. West TE, Ernst RK, Jansson-Hutson MJ, Skerrett SJ. Activation of Toll-like receptors by Burkholderia pseudomallei. BMC Immunol 2008; 9: 46.
42. Lombard Z, Brune AE, Hoal EG, Babb C, Van Helden PD, Epplen JT et al. HLA class II disease associations in Southern Africa. Tissue Antigens 2006; 67: 97-110.
43. Gordon D. Viewing and editing assembled sequences using Consed. In: Baxevanis AD et al. (eds). Current Protocols in Bioinformatics, John Wiley & Sons, Inc., chapter 11, unit 11. 2. 2003.
44. Gordon D, Abajian C, Green P. Consed: a graphical tool for sequence finishing. Genome Res 1998; 8: 195-202.
45. Bochud PY, Hawn TR, Aderem A. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J Immunol 2003; 170: 3451-3454.
46. Storm N, Darnhofer-Patel B, van den Boom D, Rodi CP. MALDI-TOF mass spectrometry-based SNP genotyping. Methods Mol Biol 2003; 212: 241-262.
47. Olomolaiye O, Wood NA, Bidwell JL. A novel NlaIII polymorphism in the human IL-6 promoter. Eur J Immunogenet 1998; 25: 267.